Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...

March is Colorectal Cancer Awareness Month, and it’s important to know the risks that come along with it. Vice President of ...

Colorectal cancer is the third-leading cause of cancer death for both men and women in the U.S., according to the American ...

A discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with ...

Preventive screenings for cancer declined during the pandemic, with lockdowns, social distancing and COVID-19 surges keeping many from needing mammograms and colonoscopies. But breast and colon ...

Cancer cells work together to source nutrients from their environment—a cooperative process that was previously overlooked by scientists but may be a promising target for treating cancer. "We ...

A new study highlights the role of inflammatory biomarkers, mitotic index, and imatinib adherence in predicting survival outcomes in high-risk gastrointestinal stromal tumours.

March is Colorectal Cancer Awareness Month and the Cancer Wellness Foundation’s Women in Blue campaign is underway.Colorectal cancer is the second leading cause of cancer deaths in men and women, ...

A unique protein designed by Cedars-Sinai Cancer investigators can cross the protective blood–brain barrier safely and deliver therapy directly into cancerous tumor cells, a preclinical study shows.

At present there is no established adjuvant treatment for GIST, but several ongoing studies have explored imatinib in the adjuvant setting. One study randomized patients to receive imatinib or ...